Health on MSN

Do peptide injections really work—and are they safe?

Fact checked by Nick Blackmer Peptides have become a buzzy wellness trend, promoted for longevity and a range of health ...

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated ...

Sermorelin.com Launches Physician-Led Telehealth Platform Dedicated to Sermorelin Peptide Therapy as Clinician Interest in GLP-1 Combination Protocols Grow

New platform connects patients with licensed providers offering sermorelin under medical supervision, supported by a growing body of peer-reviewed research and an emerging community of clinicians and ...
EurekAlert!

New study identifies growth hormone receptor as possible target to improve lung cancer treatment

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of Molecular Science ...
BioSpace

FDA approves Novo Nordisk’s Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

"Daily injections have defined the growth disorder treatment paradigm for more than 40 years. Our scientific leadership and focus on advancing care in rare diseases led us to the development of ...

Sermorelin.com Launches New Peptide Therapy Program for GLP-1 Patients

Sermorelin.com Unveils Telehealth Peptide Treatment for Lean Mass Preservation Sheridan, United States - February 27, ...
MarketWatch

FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

The MarketWatch News Department was not involved in the creation of this content. -- New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short ...
Morningstar

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

PLAINSBORO, N.J., Feb. 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® ...
Healio

FDA approves three new pediatric indications for once-weekly growth hormone injection

Please provide your email address to receive an email when new articles are posted on . Somapacitan-beco is a once-weekly growth hormone injection. New indications expand treatment options for ...